AZRX - AzurRx BioPharma, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
3.08
-0.05 (-1.60%)
As of 9:44AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.13
Open3.08
Bid2.98 x 100
Ask3.12 x 200
Day's Range3.08 - 3.08
52 Week Range2.40 - 5.25
Volume294
Avg. Volume54,179
Market Cap35.587M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-1.42
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    AzurRx BioPharma to Present at the Biotech Showcase 2018 Conference (January 8th)

    BROOKLYN, N.Y., Dec. 04, 2017-- AzurRx BioPharma, Inc., a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company will ...

  • Why AzurRx BioPharma Inc’s (AZRX) Investor Composition Impacts Your Returns
    Simply Wall St.10 days ago

    Why AzurRx BioPharma Inc’s (AZRX) Investor Composition Impacts Your Returns

    In this analysis, my focus will be on developing a perspective on AzurRx BioPharma Inc’s (NASDAQ:AZRX) latest ownership structure, a less discussed, but important factor. When it comes to ownershipRead More...

  • GlobeNewswire10 days ago

    AzurRx BioPharma to Present at the 2017 LD Micro 10th Annual Main Event Conference (December 5th)

    BROOKLYN, N.Y., Dec. 01, 2017-- AzurRx BioPharma, Inc., a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company will ...

  • GlobeNewswire2 months ago

    AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier (IMPD) Submission

    BROOKLYN, N.Y., Oct. 20, 2017-- AzurRx BioPharma Inc., announced the submission of an Investigational Medicinal Product Dossier for its lead product MS1819-SD, a recombinant lipase for the treatment of ...

  • GlobeNewswire2 months ago

    AzurRx Announces Addition of Dr. Vern Lee Schramm to the Board of Directors

    NEW YORK, Oct. 16, 2017-- AzurRx BioPharma, Inc. a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases today announced the appointment of Dr. Vern ...

  • Healthcare Industry Trends And Its Impact On AzurRx BioPharma Inc (AZRX)
    Simply Wall St.2 months ago

    Healthcare Industry Trends And Its Impact On AzurRx BioPharma Inc (AZRX)

    AzurRx BioPharma Inc (NASDAQ:AZRX), a USD$40.21M small-cap, operates in the healthcare industry, which faces demand for new drug development to meet new or persistent chronic illnesses, and ongoing need forRead More...

  • Zacks Small Cap Research2 months ago

    AZRX: Update on MS1819 Phase II Trial

    By John Vandermosten, CFA NASDAQ:AZRX AzurRx BioPharma, Inc. (NASDAQ:AZRX) announced an update to their Phase IIa Trial outcomes for MS1819.  The company announced interim results for the first six patients ...

  • GlobeNewswire2 months ago

    AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI)

    BROOKLYN, N.Y., Sept. 27, 2017-- AzurRx BioPharma Inc., today provided an update on the first six treated patients in its ongoing Phase IIa trial of MS1819-SD, a recombinant lipase, for the treatment of ...

  • GlobeNewswire3 months ago

    AzurRx Announces Appointment of Maged Shenouda as Chief Financial Officer

    NEW YORK, Sept. 25, 2017-- AzurRx BioPharma, Inc. a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases today announced the appointment of Maged ...

  • ACCESSWIRE3 months ago

    MicroCap Review Magazine Fall 2017 Issue Now Available

    The Digital Issue of the Fall 2017 MicroCap Review Magazine, The Official Magazine for the MicroCap Stock Market, can be read on www.StockNewsNow.com LOS ANGELES, CA / ACCESSWIRE / September 5, 2017 / ...

  • Zacks Small Cap Research3 months ago

    AZRX: Fall Data Announcement for MS 1819

    AzurRx BioPharma, Inc. (AZRX) filed their second quarter 10-Q on August 14th providing a financial update on the company’s second quarter performance.  Highlights for the quarter include issuance of a convertible note with Lincoln Park Capital Fund, the closure of $5.0 million in private financing and an update on the MS 1819 Phase II trial.  Subsequent to the end of the quarter, AzurRx entered into a sublicense agreement with TransChem that will provide access to species specific drug action with the benefit of limited side effects and also announced that a 6th patient had been enrolled in the Phase IIa Exocrine Pancreatic Insufficiency (EPI) trial.

  • Zacks Small Cap Research8 months ago

    AZRX: MS 1819 Trial, First Look Positive; 2016 Results

    By John Vandermosten, CFA NASDAQ:AZRX On April 11th, AzurRx BioPharma, Inc. (NASDAQ:AZRX) provided a first look at its open label Phase IIa trial investigating the use of MS 1819 for the treatment of exocrine ...

  • Accesswire9 months ago

    LifeSci Capital Initiates Coverage of AzurRx BioPharma

    Developing Oral Recombinant Products to address Gastrointestinal Diseases and Microbiome Related Conditions; Report Available here: http://www.lifescicapital.com/equity-research/AzurRx/ NEW YORK, NY / ...

  • Zacks Small Cap Research11 months ago

    AZRX: Non-systemic Focus on the GI Market

    The lead compound, MS 1819, is a yeast-derived lipase enzyme used to compensate for exocrine pancreatic insufficiency (EPI).  The compound has several superior characteristics compared to standard EPI therapy, demonstrating increased efficacy in low pH environments and derivation from a non-porcine source.  Currently MS 1819 is in a Phase 2 trial which we anticipate will be concluded before year end 2017. The company’s second compound in development is AZX 1101.  This is a recombinant β-lactamase derived from a bacterial source to address hospital-acquired infections acquired as a result of antibiotic use.  AZX 1101 is currently in preclinical development and will soon commence in vivo studies in animal models.  While the market opportunity is substantial, due to the early stage of development we do not attach any value to AZX 1101 in our analysis.

  • GuruFocus.com11 months ago

    Is AzurRx About to Transform the Gastrointestinal Treatment Industry?

    Company is working on a procedure that may be a pivotal change

  • GuruFocus.com11 months ago

    An Emerging Leader to Treat Gastrointestinal Disease

    AzurRX BioPharma is making incredible headway in gastrointestinal care